E‐E Ke

646 total citations
12 papers, 315 citations indexed

About

E‐E Ke is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, E‐E Ke has authored 12 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in E‐E Ke's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). E‐E Ke is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). E‐E Ke collaborates with scholars based in China, India and Norway. E‐E Ke's co-authors include Yi‐Long Wu, Qing Zhou, Xu‐Chao Zhang, Zhihong Chen, Jin‐Ji Yang, Feiyu Niu, Qiuyi Zhang, Wen‐Zhao Zhong, Jian Su and Hai‐Yan Tu and has published in prestigious journals such as Journal of Clinical Oncology, Oncotarget and BMC Cancer.

In The Last Decade

E‐E Ke

11 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E‐E Ke China	8	239	200	80	51	32	12	315
Kakeru Hisakane Japan	10	215 0.9×	179 0.9×	77 1.0×	67 1.3×	27 0.8×	35	336
Margaret Kolb United States	4	288 1.2×	262 1.3×	74 0.9×	48 0.9×	24 0.8×	5	365
Alketa Hamzaj Italy	8	208 0.9×	151 0.8×	117 1.5×	89 1.7×	57 1.8×	13	295
Yoshiko Urata Japan	11	237 1.0×	241 1.2×	51 0.6×	33 0.6×	20 0.6×	34	322
Javier Rodríguez Spain	11	185 0.8×	247 1.2×	40 0.5×	34 0.7×	83 2.6×	20	351
Yoshihiro Hattori Japan	9	188 0.8×	215 1.1×	54 0.7×	23 0.5×	18 0.6×	28	298
Qing Chang China	7	179 0.7×	239 1.2×	55 0.7×	32 0.6×	29 0.9×	21	308
F. Bustin Belgium	6	354 1.5×	336 1.7×	122 1.5×	47 0.9×	19 0.6×	11	459
Kaoru Irisa Japan	9	236 1.0×	214 1.1×	76 0.9×	48 0.9×	24 0.8×	16	333
Diana Gernhardt United States	7	200 0.8×	248 1.2×	135 1.7×	56 1.1×	22 0.7×	8	338

Countries citing papers authored by E‐E Ke

Since Specialization

Citations

This map shows the geographic impact of E‐E Ke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E‐E Ke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E‐E Ke more than expected).

Fields of papers citing papers by E‐E Ke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E‐E Ke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E‐E Ke. The network helps show where E‐E Ke may publish in the future.

Co-authorship network of co-authors of E‐E Ke

This figure shows the co-authorship network connecting the top 25 collaborators of E‐E Ke. A scholar is included among the top collaborators of E‐E Ke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E‐E Ke. E‐E Ke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Chen, Liangyu, Jingshen Wu, Chong Wang, et al.. (2024). Targeting Fascin1 maintains chondrocytes phenotype and attenuates osteoarthritis development. Bone Research. 12(1). 50–50. 2 indexed citations

Liu, Si‐Yang Maggie, Jie Huang, Jia‐Yi Deng, et al.. (2023). PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. Science Bulletin. 69(4). 535–543. 18 indexed citations

Zhang, Jia‐Tao, Song Dong, Jiaying Zhou, et al.. (2022). Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers. Thoracic Cancer. 13(9). 1333–1341. 2 indexed citations

Yang, Changsheng, et al.. (2021). Targeting Filamin A alleviates ovariectomy-induced bone loss in mice via the WNT/β-catenin signaling pathway. Cellular Signalling. 90. 110191–110191. 13 indexed citations

Zhang, Qi, Xu‐Chao Zhang, Jin‐Ji Yang, et al.. (2018). EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib. Journal of Thoracic Oncology. 13(9). 1415–1421. 56 indexed citations

Zhang, Yichen, E‐E Ke, Zhihong Chen, et al.. (2017). P3.02b-095 Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs. Journal of Thoracic Oncology. 12(1). S1249–S1249.

Ke, E‐E, Qing Zhou, Qiuyi Zhang, et al.. (2017). A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. Journal of Thoracic Oncology. 12(9). 1368–1375. 74 indexed citations

Tu, Hai‐Yan, E‐E Ke, Yue‐Li Sun, et al.. (2017). The predictive value of uncommon EGFR mutation in patients with non-small-cell lung cancer.. Journal of Clinical Oncology. 35(15_suppl). 9028–9028. 1 indexed citations

Niu, Feiyu, Qing Zhou, Jin‐Ji Yang, et al.. (2016). Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer. 16(1). 149–149. 107 indexed citations

10.

Zhang, Qiuyi, E‐E Ke, Feiyu Niu, et al.. (2016). The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma. Oncotarget. 8(3). 4994–5002. 9 indexed citations

11.

Ke, E‐E & Yi‐Long Wu. (2016). Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. Therapeutic Advances in Respiratory Disease. 10(3). 256–264. 14 indexed citations

12.

Ke, E‐E, Qing Zhou, & Yi‐Long Wu. (2015). Emerging paradigms in targeted treatments for Asian patients with NSCLC. Expert Opinion on Pharmacotherapy. 16(8). 1167–1176. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact